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Thrombin-promoted release of UDP-glucose from
human astrocytoma cells
SM Kreda, L Seminario-Vidal, C van Heusden and ER Lazarowski
Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Background and purpose: The P2Y14 receptor is activated by UDP-sugars, most potently by UDP-glucose, but not by free
nucleotides, suggesting that UDP-glucose is the cognate agonist for this receptor. However, evidence for regulated release of
UDP-glucose is scarce. In the present study, the occurrence of receptor-promoted release of UDP-glucose was investigated,
using 1321N1 human astrocytoma cells.
Experimental approach: UDP-glucose release and hydrolysis were measured using HPLC-based techniques. Phospholipase C
activation and actin cytoskeleton reorganization were assessed by measuring inositol phosphate formation and fluorescence
confocal microscopy, respectively.
Key results: Thrombin and the protease-activating receptor-1 (PAR1) peptide TFLLRNPNDK (PAR1-AP) evoked the release of
UDP-glucose and ATP, which was accompanied by enhanced inositol phosphate formation. Although carbachol promoted
fourfold greater inositol phosphate formation than thrombin, it failed to promote nucleotide release. Thrombin-promoted
nucleotide release was inhibited by BAPTA-AM, brefeldin A and cytochalasin D, and was insensitive to Pertussis toxin and
PI3-kinase inhibitors. Thrombin, but not carbachol, induced actin cytoskeleton reorganization, a hallmark of Rho activation
in 1321N1 cells. However, PAR-promoted UDP-glucose release was not affected by Rho kinase inhibition.
Conclusions and implications: PAR1-evoked UDP-glucose release reflected a Ca2þ -dependent mechanism, engaging
additional signalling independently of Gi and Rho kinase activation and requiring a functional actin cytoskeleton and Golgi
structures. Our study demonstrates the occurrence of Ca2þ -dependent release of UDP-glucose from astrocytoma cells in
response to a physiologically relevant stimulus, that is, a G-protein-coupled receptor agonist. Given the presence of P2Y14
receptors in astrocytes, UDP-glucose may have important autocrine/paracrine functions in the brain.
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Introduction
ATP and other nucleotides are released from cells in a
regulated manner to accomplish extracellular signalling
functions through activation of P2X and P2Y purinergic
receptors (Burnstock and Williams, 2000; Burnstock, 2006).
P2X receptors, comprising seven species (P2X1–P2X7), are
ATP-gated ion channels. P2Y receptors belong to the super-
family of G-protein-coupled receptors. At least eight P2Y
receptor species have been identified, seven of which are
activated by adenine and/or uridine nucleoside di- and
triphosphates. The P2Y1, P2Y12 and P2Y13 receptors are
activated by ADP. The P2Y2 receptor is activated by both ATP
and UTP, and the P2Y4 (human) and P2Y6 receptors are
activated by UTP and UDP, respectively. Unlike other P2
receptors, the P2Y14 receptor is activated by UDP-sugars,
most potently by UDP-glucose, and is not activated by di- or
triphosphonucleotides (Chambers et al., 2000).
Studies using heterologously expressed P2Y14 receptor
have revealed a previously unnoticed accumulation of
endogenous receptor agonist in extracellular solutions.
Taking advantage of the selectivity of UDP-glucose pyropho-
phorylase in catalyzing the UDP-glucose-dependent conver-
sion of pyrophosphate to UTP, UDP-glucose was identified
and quantified with nanomolar sensitivity in the extra-
cellular medium of many tissues and cell lines, including
1321N1 human astrocytoma cells (Lazarowski et al., 2003b).
However, whether extracellular accumulation of UDP-
glucose reflects a regulated mechanism of nucleotide release
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is not well defined. With the exception of nerve terminals
and other specialized tissues that release ATP from secretory
granules through Ca2þ -regulated exocytosis, how nucleo-
tides are released from most cell types is poorly understood.
A major limitation in this understanding was, until recently,
the paucity of pharmacological tools to induce nucleotide
release in a regulated manner.
Thrombin and other serine proteases activate a family of
four G-protein-coupled receptors, referred to as protease-
activated receptors (PAR1–PAR4). Recently, Joseph et al.
(2003) illustrated that activation of 1321N1 cells with
thrombin resulted in enhanced release of ATP in a Ca2þ -
dependent manner. Subsequently, we observed that addition
of thrombin to 1321N1 cells resulted in enhanced extra-
cellular accumulation of UDP-glucose, in addition to ATP
release (Lazarowski, 2006). However, whether thrombin-
increased UDP-glucose accumulation reflected PAR-promoted
UDP-sugar release and whether the signalling pathways were
potentially involved in such a release were not addressed. In
the present study, we investigated potential mechanisms
involved in thrombin-elicited UDP-glucose release in
1321N1 cells. As the P2Y14 receptor is abundantly expressed
in brain astrocytes (Moore et al., 2003), illustration of the
regulated release of UDP-glucose by 1321N1 astrocytoma
cells would provide support for the physiological signifi-
cance of the P2Y14 receptor in the brain.
Methods
Cell culture
1321N1 Human astrocytoma cells were grown in 5% calf
serum-supplemented Dulbecco’s modified Eagle’s medium
for 5 days to near confluence (B5 to 8105 cells cm2) on
either 35 mm (9.6 cm2) plastic dishes for real-time ATP
measurements or 24-well plastic plates (1.8 cm2) for UDP-
glucose and inositol phosphate measurements, as described
previously (Lazarowski et al., 2003b). For confocal micro-
scopy studies, cells were grown to subconfluence on eight-
well Lab-Tek II glass chamber slides (Nalge Nunc Int.,
Naperville, IL, USA). Cells were used within passages 3–12;
a gradual decline in PAR1-promoted second messenger
production was noted during subsequent passages.
UDP-glucose release
Cultures were rinsed and preincubated in serum-free mini-
mum essential medium for 2 h to allow recovery from
mechanical stress during medium changes (Lazarowski
et al., 2003b). Incubations were initiated by the addition of
drugs, and aliquots (200 ml) were removed at the indicated
times. Collected samples were heated (95 1C, 2 min) to
inactivate potentially secreted nucleotidases, and stored
at 20 1C for nucleotide analysis. UDP-glucose was assayed
based on the UDP-glucose pyrophosphorylase-catalyzed
conversion of [32P]pyrophosphate to [32P]UTP, followed by
HPLC analysis of the resulting [32P]species, as described
previously (Lazarowski et al., 2003b).
Measurement of UDP-[3H]glucose metabolism
Cells were rinsed and preincubated as above, and subse-
quently incubated for the indicated times in 0.3 ml mini-
mum essential medium in the presence of 0.1 mCi UDP-
[3H]glucose. The resulting species were analyzed by HPLC as
described previously (Lazarowski et al., 2003b).
ATP release
ATP measurements were performed in real time, as described
recently (Okada et al., 2006). Briefly, 1321N1 cells were
rinsed twice with Hanks’ balanced salt solution supplemen-
ted with 1.2 mM CaCl2, 1.2 mM MgCl2 and 25 mM HEPES (pH
7.4). Cultures were preincubated for 1 h at 37 1C in 1 ml
Hanks’ balanced salt solution and transferred to a Turner
TD-20/20 luminometer (Turner Biosystems, Sunnyvale, CA,
USA). Luciferase (4mg ml1; 15 to 30106 light units mg1)
and luciferin (60 mM) were added, and luminescence mea-
sured every 30 s. To minimize ATP hydrolysis, the nucleoti-
dase inhibitor b,g-methylene ATP (b,g-metATP; 300 mM) was
added to the cells 5–10 min before the administration of
drugs. Calibration curves using known concentrations of
ATP were calculated at the end of each assay.
Inositol phosphate accumulation
The cells were incubated overnight in 0.5 ml of inositol-free
HEPES-buffered Dulbecco’s modified Eagle’s medium (pH
7.4) containing 0.5 mCi of myo-[3H]inositol. At the end of the
labelling period, cells were preincubated for 10 min in the
presence of 10 mM LiCl, followed by the addition of either
vehicle or agonist. [3H]Inositol phosphates were isolated on
Dowex anion exchange columns and quantified as described
previously (Lazarowski et al., 2003b).
Reverse transcription-PCR analysis of PARs
Total RNA was prepared from 1321N1 cells using the RNeasy
mini kit (Qiagen Inc., Valencia, CA, USA) after RNAlater
treatment (Ambion, Austin, TX, USA). Genomic DNA
contamination was removed by DNase treatment and RNA
was reverse-transcribed using SuperScript II reverse tran-
scriptase. The resulting cDNA was used as a template, and
PCR was performed at the University of North Carolina CF
Center Molecular Biology Core Lab (Chapel Hill, NC, USA)
according to the following protocol: 4 min at 94 1C, 1 min at
72 1C, 45 s at 94 1C, 1 min at 55 1C and 1 min at 72 1C for 36
cycles, followed by an 8-min incubation at 72 1C. PAR1
(GenBank M62424) primers, kindly provided by Dr JoAnn
Trejo (Department of Pharmacology, UNC, NC, USA), were as
follows: forward primer, CAGTTTGGGTCTGAATTGTGTCG;
reverse primer, TGCACGAGCTTATGCTGCTGAC. Amplified
products (predicted size, 591 bp) were sequenced at the UNC
Genome Analysis Facility.
Confocal microscopy studies
Cells were incubated with agonists and/or inhibitors, as
indicated in the figure legends. At the end of the incubation,
cells were fixed in 4% paraformaldehyde at 37 1C for 5 min,
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rinsed and permeabilized with 100% cold methanol for
2 min. The actin cytoskeleton was labelled with Alexa 488-
phalloidin (70 nM, 60 min at room temperature; Molecular
Probes, Eugene, OR, USA). The Golgi was stained with
N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-
3-pentanoyl)sphingosine (NBD C6-ceramide; 1mM, 30 min at
4 1C; Molecular Probes). Cell preparations were mounted
under a coverslip with Vectashield medium containing 4,6-
diamidino-2-phenylindole (DAPI) (Vector Labs Inc., Burlin-
game, CA, USA). Confocal microscopy analysis was per-
formed in a Leica SP2 AOBS system, using a 63 PlanApo
lens and two independent laser sources (351 nm UV and
488 nm argon); parameters were saved in a file and used
throughout the analyses.
Data analysis
UDP-glucose decay data and agonist concentration–effect
relationships were analysed using SigmaPlot 8.01 (SPSS Inc.,
Chicago, IL, USA). Differences between means were deter-
mined by Student’s t-test and were considered significant
when Po0.01.
Reagents
[g32P]ATP (3000 Ci mmol1) and myo-[3H]inositol
(20 Ci mmol1) were purchased from Amersham Pharmacia
Biotech (Piscataway, NJ, USA). UDP-glucose pyrophosphor-
ylase from baker’s yeast and b,g-metATP were obtained from
Sigma (St Louis, MO, USA). Human a-thrombin was
purchased from Enzyme Research Laboratories (South Bend,
IN, USA). The PAR1-activating peptide TFLLRNPNDK (Da-
miano et al., 1999), hereafter referred to as PAR1-AP, was
synthesized at Tufts University Peptide Synthesis Core
Facility (Sommerville, MA, USA). Alexa 488-phalloidin and
the fluorescent Golgi marker NBD C6-ceramide were pur-
chased from Molecular Probes. Rho-associated kinase
(Rho-kinase, ROCK) inhibitors Y27632 and H-1152P were
purchased from Calbiochem (La Jolla, CA, USA). Other
chemicals, of the highest purity available, were obtained
from sources previously reported (Lazarowski et al., 2003b,
2004).
Results
Stability of extracellular UDP-glucose
Studies of nucleotide release have been complicated by the
presence of nucleotidase activities flanking the nucleotide
release site (Joseph et al., 2003). In addition, nucleoside
diphosphokinase and adenylate kinase transfer the terminal
phosphate of NTP to NDP or NMP, respectively, creating
additional artifacts. Although free nucleotides (that is, NTPs
and NDPs) are substrates for most of these activities, UDP-
sugars are not metabolized by ecto-apyrases (NTPDases),
nucleoside diphosphokinase or adenylate kinase. However,
ecto-NTP pyrophosphatases (E-NPP), which hydrolyze free
nucleotides as well as cyclic nucleotides, dinucleotides and
nucleotide-sugars, are expressed on many cell types, includ-
ing 1321N1 cells (Lazarowski et al., 2000; Joseph et al., 2004).
Indeed, we have previously illustrated that radiolabelled
UDP-glucose was steadily, although relatively slowly, hydro-
lyzed on 1321N1 cells (Lazarowski et al., 2003b).
To optimize conditions that would minimize UDP-glucose
metabolism during measurements of UDP-glucose release,
we examined the effect of the E-NPP inhibitor b,g-metATP
(Joseph et al., 2004) on the stability of UDP-[3H]glucose,
added as a radiotracer to 1321N1 cells. In the absence of
b,g-metATP, UDP-[3H]glucose was gradually hydrolyzed with
first-order rate constant (k) and half-life (t1/2) values of
0.0329 min1 and 21 min, respectively (Figure 1a). [3H]Glu-
cose-1P was the [3H]-labelled product of UDP-[3H]glucose
hydrolysis on 1321N1 cells (data not shown), as previously
described (Lazarowski et al., 2003b). b,g-metATP effectively
inhibited UDP-glucose hydrolysis. Figure 1a indicates
that UDP-[3H]glucose remained essentially unchanged on
1321N1 cells after 30 min in the presence of 300 mM b,g-
metATP. The concentration–effect relationship for b,g-me-
tATP inhibition of UDP-[3H]glucose hydrolysis is illustrated
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Figure 1 b,g-methylene ATP is an effective inhibitor of hydrolysis of
UDP-glucose. (a) Confluent 1321N1 cells were incubated in the
absence (control) or presence of 300mM b,g-metATP and 0.1 mCi
UDP-[3H]glucose for the indicated times. Single exponential decay
parameters k and t1/2 were calculated as described previously
(Lazarowski et al., 2000). (b) UDP-[3H]glucose hydrolysis was
assessed after a 5-min incubation with the indicated amount of
b,g-metATP or UMP; inset, HPLC tracing (absorbance at 260 nm)
illustrating the conversion of UMP (100mM) to uridine (URID) after
5 min. (c) Effect of b,g-metATP (300mM) on the release of UDP-
glucose in response to 20 nM thrombin (5 min). (d) Calibration curve
for the UDP-glucose assay in the absence or presence of 300mM
b,g-metATP. The data represent the mean±s.d. from at least
two experiments performed in duplicate (a, b and d) or quad-
ruplicate (c).
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in Figure 1b. In the absence of an inhibitor, approximately
17% UDP-[3H]glucose was hydrolyzed within 5 min
(Figure 1b). Hydrolysis of UDP-[3H]glucose was inhibited by
approximately 50% with 10 mM b,g-metATP, and was abol-
ished with 300 mM b,g-metATP (Figure 1b). UMP, the nucleo-
tide product of E-NPP-catalyzed UDP-sugar hydrolysis, also
inhibited UDP-[3H]glucose breakdown, although less effec-
tively than b,g-metATP (Figure 1b). However, the magnitude
of UMP inhibition on UDP-glucose hydrolysis could not
be fully appreciated, because UMP itself was considerably
hydrolyzed upon its addition to cells (Figure 1b, inset).
Previously, we reported that stimulation of 1321N1 with
thrombin resulted in enhanced extracellular accumulation
of UDP-glucose (Lazarowski, 2006), suggesting that
thrombin promoted UDP-glucose release from these cells.
To further corroborate this observation, extracellular UDP-
glucose concentrations were measured in resting and
thrombin-stimulated cells, in the absence or presence of
b,g-metATP. In resting, untreated cells, the concentration
of UDP-glucose in the extracellular bulk medium was
3.7±0.3 nM (Figure 1c). This UDP-glucose concentration
reflected steady state where the rates of hydrolysis and
constitutive release are equal (Lazarowski et al., 2000). Based
on the k value obtained above (Figure 1a), the rate (v) of
release of UDP-glucose from resting cells was calculated as
v¼ kS¼40 fmol min1, where S represents UDP-glucose con-
centration at steady state (Lazarowski et al., 2000, 2003b).
Thus, in the absence of hydrolysis, that is, in the presence of
b,g-metATP, UDP-glucose concentrations in the 300 ml
medium bathing a 12 mm culture would be predicted to
increase at a pace of 0.09 nM min1 (or 0.45 nM after 5 min), a
minor increase. Indeed, average UDP-glucose concentration
after the addition of b,g-metATP to the cells for 5 min
(3.9±1.0 nM) was not significantly higher than control
values (Figure 1c). However, levels of extracellular UDP-
glucose increased to up to approximately 8 nM after the
addition of 20 nM thrombin, and to approximately 14 nM
when thrombin and b,g-metATP were added in combination
(Figure 1c). b,g-metATP itself did not interfere with the
measurement of UDP-glucose mass (Figure 1d). The most
parsimonious explanation for the results in Figure 1 is that
thrombin enhances the rate of release of UDP-glucose from
1321N1 cells. The data also suggest that, in the absence of
inhibitors, E-NPP efficiently hydrolyses UDP-glucose at the
site of release, as previously suggested for ATP (Joseph et al.,
2003).
PAR1 promotes Ca2þ -dependent release of UDP-glucose and ATP
The time course for thrombin-elicited UDP-glucose release
was examined in the presence of 300 mM b,g-metATP.
Addition of 20 nM thrombin to 1321N1 cells resulted in
enhanced accumulation of extracellular UDP-glucose (3- to
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Figure 2 Agonist-promoted UDP-glucose and ATP release in 1321N1 cells. The cells were incubated with vehicle (Ctl) or 20 nM thrombin
(Thr) for the indicated times (a and d), with vehicle, 20 nM thrombin, 100mM PAR1-AP or 300mM carbachol (Carb) for 5 min (b and e) or with
vehicle or 20 nM thrombin for 5 min following a 30-min preincubation with 10 mM BAPTA-AM (c and f). UDP-glucose (a–c) and ATP (d–f)
concentrations were measured as indicated in Methods. The data (in a–c, e and f) represent the mean±s.d. of at least three experiments
performed with quadruplicate samples. Representative tracings of ATP measurements in real time are illustrated in (d), and similar results were
obtained in six independent experiments.
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(100 mM; Figure 2b) caused a robust increase in UDP-glucose
release, consistent with the notion that PAR1 is the major
thrombin receptor expressed in 1321N1 cells (Majumdar
et al., 1998). Reverse transcription-PCR analysis (and sub-
sequent sequencing of products) verified that PAR1 tran-
scripts were expressed in these cells (data not shown). As
predicted from previous studies (Joseph et al., 2003),
thrombin and PAR1-AP also caused enhanced ATP release
from 1321N1 cells (Figures 2d and e). Changes in ATP
concentration in response to thrombin were five times
greater than that in UDP-glucose (D[ATP] B50 nM, D[UDP-
glucose] B10 nM). However, whereas UDP-glucose was
measured offline in diluted bulk medium, the ATP-sensing
luciferin–luciferase protocol (Figures 2a–c) was optimized to
assess ATP release near the cell surface (Okada et al., 2006).
Both UDP-glucose and ATP release in response to thrombin
were inhibited by incubating the cells with O,O0-Bis(2-
aminophenyl)ethyleneglycol-N,N,N0,N0-teraacetic acid, tetra-
acetoxymethyl ester (BAPTA-AM) to chelate intracellular
Ca2þ (Figures 2c and f). Unlike PAR1 agonists, the muscarinic
receptor agonist carbachol (300mM, 5min) failed to elicit UDP-
glucose and ATP release from 1321N1 cells (Figures 2b and e).
The above-mentioned results indicated that thrombin-
elicited UDP-glucose and ATP release reflects a Ca2þ -
dependent mechanism. However, the lack of effect of
carbachol on nucleotide release was intriguing. We have
previously shown a robust presence of Gq/PLC-b/Ca
2þ -
coupled muscarinic receptors in 1321N1 cells (Lazarowski
et al., 1997). To investigate the possibility that differences
in magnitude of Gq-mediated second messenger production
between PAR-1 and muscarinic receptor activation
accounted for differences in nucleotide release, concentra-
tion–response curves for agonist-promoted UDP-glucose
release and inositol phosphate formation were generated.
Thrombin promoted UDP-glucose release and inositol
phosphate formation with EC50 values of 0.7 and 1.0 nM,
respectively (Figure 3). PAR1-AP-elicited UDP-glucose
release also occurred with a potency (EC50¼1.1 mM) similar
to that of PAR1-AP-promoted phosphoinositide breakdown
(EC50¼ 0.7mM). At maximal concentrations, both thrombin
and PAR1-AP increased UDP-glucose release and inositol
phosphate formation by 7- to 9- and 4-folds, respectively
(Figure 3). Carbachol promoted a robust (12-fold) increase in
inositol lipid hydrolysis (Figure 3b) but elicited negligible
UDP-glucose release at all concentrations tested (Figure 3a).
These results suggest that receptor-promoted Gq/PLC-b
activation is not sufficient to elicit nucleotide release from
1321N1 cells.
UDP-glucose release is independent of Gi, PI3-kinase and Rho
kinase
In addition to Gq, PAR1 couples to G12/13 and Gi families of
heterotrimeric G proteins (Majumdar et al., 1998; Ellis et al.,
1999). In 1321N1 cells, PAR-promoted activation of G12/13
leads to the activation of Rho GTPases. Among them, RhoA
and its effector ROCK have been linked to actin cytoskeleton
reorganization and changes in cell shape in 1321N1 cells
(Majumdar et al., 1998). We investigated the effect of
thrombin on cytoskeleton reorganization by confocal micro-
scopy analysis of cells stained with fluorescently labelled
phalloidin, which binds to F-actin. Resting 1321N1 cells
displayed a fusiform and star-like shape (stellation), with
long and thin cellular projections (usually contacting other
cells) as well as short spine-like projections. The cells were
flat and well attached to the substrate with actin stress fibres
organized mainly along the longitudinal axes (Figure 4a).
Incubation of 1321N1 cells with thrombin resulted in
marked changes in cell shape and organization of the actin
cytoskeleton. Most noticeable were the rounding and
retraction of the cell body, loss of cell projections (reverse-
stellation) and clustering of cells in bunches. Cell height
increased notably, as indicated by xz laser-scanning analysis
(data not shown). Intense actin-associated fluorescence was
identified in the subplasma membrane compartment as a
cortical ring (Figure 4a), as previously described (Coleman
and Olson, 2002). Actin stress fibres decreased greatly. After
30 min of thrombin addition, many cells displayed blebbing-
containing actin (Figures 4a, centre). In contrast to these
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Figure 3 Concentration–response relationships for agonist-
promoted UDP-glucose release and inositol phosphate formation
in 1321N1 cells. (a) UDP-glucose release was measured following a
5-min incubation of cells in the presence of the indicated
concentration of thrombin, PAR1-AP or carbachol. (b) myo-[3H]
inositol-labelled 1321N1 cells were incubated for 20 min in the
presence of agonists, and the resulting [3H]inositol phosphate
accumulation quantified, as described in Methods. The results
(mean±s.d.) are from two (a) or three (b) independent experiments
performed with triplicate samples.
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observed in response to carbachol (data not shown).
Preincubation of 1321N1 cells with the ROCK inhibitor
Y27632 nearly abolished the effect of thrombin on cell
rounding, reverse-stellation and cell blebbing (Figure 4a).
These results are consistent with the notion that PAR1
activates G12/13, which in turn promotes activation of the
guanine nucleotide exchange factor (GEF) RhoGEF, upstream
of Rho/ROCK (Trejo, 2003). However, Y27632, as well as
H-1152, another selective ROCK inhibitor, failed to affect the
magnitude of UDP-glucose release in thrombin-stimulated
cells (Figure 4b).
Pertussis toxin, which ADP-ribosylates and inhibits Gai/o
proteins, also failed to affect thrombin-promoted UDP-
glucose release. Consistent with these results, PI3-kinase
(which is activated downstream of Gi) was not involved in
UDP-glucose release, as judged by the absence of effect of
wortmannin on thrombin-elicited UDP-glucose release
(Figure 4b).
Exocytotic vs transport/conductive mechanisms
UDP-sugars are synthesized in the cytosol and transported to
the lumen of the endoplasmic reticulum (ER) and the Golgi
apparatus via UDP-sugar/UMP antiporters. These transpor-
ters translocate UDP-sugars from the cytosol to the lumen of
the Golgi, using luminal UMP as the antiporter substrate
(Hirschberg et al., 1998; Ishida and Kawakita, 2004).
Although all known UDP-sugar transporters are ER/Golgi
resident proteins, the possibility that an unknown UDP-
glucose/UMP antiporter was expressed in the plasma
membrane of 1321N1 cells, thereby exchanging cytosolic
UDP-glucose for extracellular UMP, has not been formally
examined. Preliminary experiments in our lab (performed in
the absence of b,g-metATP) suggested that UMP enhanced
thrombin-promoted UDP-glucose release (data not shown).
However, this effect was related to the inhibitory action
of UMP on UDP-glucose hydrolysis (Figure 1b). As illustrated
in Figure 5b, addition of exogenous UMP to the cells
caused no changes in either basal or stimulated release of
UDP-glucose (measured in the presence of b,g-metATP).
These results argue against the possibility that UDP-glucose
release occurred via a plasma membrane UDP-sugar/UMP
antiporter.
Alternatively, UDP-glucose release may reflect an exocyto-
tic process (Lazarowski et al., 2003a). The fungal metabolite
brefeldin A (BFA) disrupts retrograde movements along the
secretory pathway, disassembling the Golgi network (Dinter
and Berger, 1998; Shinotsuka et al., 2002). Incubation of
1321N1 cells with 3mM BFA for 60 min provoked profound
changes in Golgi morphology, as illustrated by the striking





























Figure 4 Lack of effect of Rho-kinase inhibitors, pertussis toxin and wortmannin on UDP-glucose release. (a) Y27632 inhibits thrombin-
promoted cell rounding and actin cytoskeleton changes. 1321N1 cells were incubated for 30 min with vehicle or 20 nM thrombin in the
absence or presence of 10mM Y27632. Actin cytoskeleton was labelled with fluorescent phalloidin and visualized by confocal microscopy, as
described in Methods; scale bar, 40mm. (b) cells were preincubated in the presence of 10mM Y27632 (30 min), 10mM H-1152 (30 min), 100 nM
wortmannin (15 min) or 60 ng ml1 pertussis toxin (PTX, 18 h). The cells were subsequently incubated for an additional 10 min in the absence
or presence of 20 nM thrombin. Extracellular UDP-glucose was measured as described in Methods. The results are expressed as fold increase
relative to control (vehicle), and represent the mean±s.d. from two independent experiments, each performed in quadruplicate.
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decrease in fluorescence attained with the Golgi marker NBD
C6-ceramide (Figures 5a and b). Treatment with BFA did
not affect the overall cell morphology, as visualized by
the actin fluorescent dye phalloidin (Figures 5c and d),
and differential interface contrast images (data not shown).
We have shown that BFA reduced basal UDP-glucose
levels, consistent with the hypothesis that UDP-sugar release
from resting cells is associated with the export of glycocon-
jugates to the cell surface, via the constitutive pathway
(Lazarowski et al., 2003a). In our present experiments, BFA
almost completely blocked thrombin (20 nM)-promoted
UDP-glucose release (Figure 5e). Brefeldin A caused only
partially inhibited thrombin-promoted [3H]inositol
phosphate formation (control, 4790±360 cpm; BFA,
4610±280 cpm; 20 nM thrombin, 12 770±1680 cpm; throm-
bin plus BFA, 9050 ±1187 cpm; Po0.001; n¼4), which
was consistent with the relatively rapid cell surface turn-
over of PAR1 (Trejo, 2003). BFA did not affect carbachol-
elicited phosphoinositide breakdown (300 mM carbachol,
68 730±9880 cpm; carbachol and BFA, 66 870±2130 cpm;
n¼4), indicating that Gq-promoted signalling was preserved
in BFA-treated cells. Thus, thrombin-evoked second
messenger production, although diminished by BFA, was
still robust. The partial (44%) reduction of PAR1-elicited
signalling in the presence of BFA could not account for
the dramatic reduction in PAR1-evoked UDP-glucose release
observed under the same conditions. Furthermore, disrup-
tion of the cytoskeleton with cytochalasin D, a condition
that inhibited vesicle exocytosis as well as ATP release in
epithelial cells (Kreda et al., 2007), decreased (430% inhibi-
tion) thrombin-elicited UDP-glucose release (Figure 5e) with-
out affecting thrombin-evoked [3H]inositol phosphate for-
mation (data not shown). Altogether, the results in Figure 5
suggest that the secretory pathway was involved, at least in
part, in both basal and in PAR-evoked UDP-glucose release
from 1321N1 cells.


























Figure 5 Inhibition of vesicle trafficking/exocytosis impairs receptor-promoted responses. (a–d) Brefeldin A (BFA) disrupted Golgi structures.
1321N1 cells were incubated for 1 h with vehicle (a, c) or 3 mM BFA (b, d). Golgi structures were labelled with NBD C6-ceramide (a, b) and
visualized by confocal microscopy. Actin cytoskeleton was labelled with fluorescent-phalloidin (c, d) to assess cell morphology; scale bar,
40mm. (e) UDP-glucose measurements were performed in cells preincubated for 60 min in the presence of vehicle (Veh), 3 mM BFA or 10mM
cytochalasin D (CytD). At the end of this period, 300mM b,g-metATP was added to the cells. Cells were incubated for an additional 10 min in
the absence or presence of 300mM UMP and/or 20 nM thrombin, as indicated. The data represent the mean±s.d. from at least two
experiments performed in quadruplicates.
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Discussion and conclusions
The major finding of the present study is that UDP-glucose
release from 1321N1 astrocytes reflects a receptor-regulated,
Ca2þ -dependent event, which requires the integrity of the
secretory pathway. It was previously observed that 1321N1
cells release UDP-glucose constitutively (Lazarowski et al.,
2003b), and that addition of thrombin to these cells resulted
in increased accumulation of this nucleotide-sugar in the
extracellular medium (Lazarowski, 2006). Our present work
demonstrates that increased UDP-glucose accumulation in
the medium of thrombin-stimulated cells reflected receptor-
promoted release of this UDP-sugar rather than inhibition of
nucleotide hydrolysis (Figure 1). We illustrated that throm-
bin promoted both UDP-glucose release and second messen-
ger production with a potency consistent with this protease
acting on PAR1 (Trejo, 2003). We also demonstrated that the
PAR1-selective peptide TFLLRNPNDK elicited second mes-
senger production and UDP-glucose release in 1321N1 cells
with an efficacy similar to that of thrombin (Figure 3).
Finally, Reverse transcription-PCR analysis confirmed ex-
pression of PAR1 transcripts in these cells. Our data strongly
suggest that thrombin-promoted UDP-glucose release in
1321N1 cells was mediated by activation of PAR1.
Recently, we illustrated that elevation of Ca2þ (with
ionomycin) was enough to induce nucleotide release from
airway epithelial goblet cells, an event associated with Ca2þ -
triggered exocytosis of mucin granules (Kreda et al., 2007).
Consistent with the involvement of Ca2þ in nucleotide
release, thrombin-evoked UDP-glucose release from 1321N1
cells was inhibited by BAPTA (added to cells as BAPTA-AM;
Figure 2). However, a surprising finding of our current study
was that agonist-promoted nucleotide release inversely
correlated with the receptors’ ability to evoke Gq/PLC
signalling. The muscarinic M3 receptor is abundantly
expressed on 1321N1 cells (Stephan and Sastry, 1992), and
activation of these Gq-coupled/Ca
2þ -mobilizing receptors
did not result in UDP-glucose release. These results are in line
with previous studies illustrating that carbachol evoked only
minor ATP release from 1321N1 cells, relative to thrombin
(Joseph et al., 2003). One possible explanation for our data is
that UDP-glucose release in thrombin-stimulated 1321N1
cells reflected signalling downstream of PAR1/Gq that
differed, spatially and/or temporally, from M3-receptor-
evoked Gq signalling. Alternatively, as PAR1 couples to Gq,
G12/13 and Gi in 1321N1 cells, whereas muscarinic receptors
on 1321N1 cells couple only to Gq (Majumdar et al., 1998),
G12/13 and/or Gi effectors may participate in thrombin-
promoted nucleotide release from these cells. Our data do
not support the involvement of Gi in PAR-stimulated UDP-
glucose release. Pertussis toxin, which inhibits Gi signalling
in 1321N1 cells (Parr et al., 1994), and wortmannin, an
inhibitor of PI3-kinase (PI3-kinase-g isoform is activated by
Gi (Rickert et al., 2000)), had no effect on PAR1-stimulated
UDP-glucose release (Figure 4b). It is well established that
PAR1 coupling to G12/13 leads to RhoGEF-mediated activa-
tion of Rho GTPases. A well-characterized downstream
effector of Rho in 1321N1 cells is ROCK, which regulates
morphologic changes. In 1321N1 cells, thrombin (but not
carbachol) promotes myosin light change phosphorylation
and cell shape changes, for example, cell rounding
(Majumdar et al., 1998; Coleman and Olson, 2002).
Although thrombin-elicited cell rounding was abolished in
the presence of the ROCK inhibitor Y27632 (Figure 4a),
thrombin-promoted UDP-glucose release was not affected by
ROCK inhibitors (Figure 4b). Possibly, PAR-promoted nucleo-
tide release could reflect involvement of effectors down-
stream of G12/13 other than ROCK, for example, TKs,
A-kinase anchoring protein, Ras GTPase activating protein,
cadherin and PLC-e (Kurose, 2003).
Apart from the signalling involved, regulated release of
nucleotides is considered to occur in the following two
possible modes: (i) cytosolic nucleotide release through
channels or transporters and (ii) exocytotic release of
nucleotide-enriched vesicles (Lazarowski et al., 2003a; Kreda
et al., 2007). Candidate transporters mediating UDP-glucose
release from the cytosol of 1321N1 cells are SLC35 translo-
cators, which transport nucleotide-sugars across subcellular
membranes (Hirschberg et al., 1998; Ishida and Kawakita,
2004). SLC35 translocators transport UDP-glucose and other
UDP-sugars from the cytosol to the ER/Golgi, using luminal
UMP as the antiporter substrate (Hirschberg et al., 1998;
Ishida and Kawakita, 2004). However, UDP-sugar/UMP
translocators does not appear to be expressed/inserted in
the plasma membrane of 1321N1 cells, as addition of UMP
to the extracellular medium failed to increase UDP-glucose
release (Figure 5). Moreover, the robust ecto-50-nucleotidase
activity present on 1321N1 cells (Figure 1b) makes it unlikely
that endogenous UMP (for example, generated from released
UTP; Lazarowski et al., 1997) accumulates on 1321N1 cell
surfaces. Furthermore, the fact that UDP-glucose release from
thrombin-stimulated 1321N1 cells was accompanied by
enhanced ATP release suggests that a non-selective mechan-
ism was involved. We cannot rule out that channels or
transporters, other than SLC35, facilitated cytosolic nucleo-
tide release from 1321N1 cells. For example, connexin and
pannexin hemichannels have been proposed as ATP chan-
nels in several types of cells (Cotrina et al., 1998; Stout et al.,
2002; Bao et al., 2004; De Vuyst et al., 2005; Eltzschig et al.,
2006; Pelegrin and Surprenant, 2006; Huang et al., 2007).
The potential contribution of connexin hemichannels to
nucleotide release from astrocytes is unclear (Scemes et al.,
2000; Coco et al., 2003; Bowser and Khakh, 2007).
Neurons, chromaffin cells, platelets, mast cells and
pancreatic acinar cells package ATP in synaptic vesicles,
chromaffin granules or dense core granules, which, upon
stimulation with, for instance Ca2þ mobilizing agonists, fuse
with the plasma membrane and release their contents into
the extracellular space, a process commonly referred to as
regulated exocytosis (Dean et al., 1984; Evans et al., 1992;
Gualix et al., 1999; Sorensen and Novak, 2001). Coco et al.
(2003) have illustrated that an ATP-rich fraction from
astrocyte homogenates co-sedimented with secretogranin
II-containing vesicles on sucrose density gradients, and
that mechanically induced ATP release was Ca2þ -dependent
and was inhibited by tetanus neurotoxin and the v-ATPase
inhibitor bafilomycin A1. These findings support the hy-
pothesis that ATP release in mechanically stimulated astro-
cytes occur via regulated exocytosis (Coco et al., 2003). Our
observation that UDP-glucose is released concomitantly with
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ATP from PAR-stimulated 1321N1 astrocytoma cells supports
the involvement of vesicles in nucleotide release from
astrocytes. UDP-glucose is utilized in the lumen of the ER
and Golgi for quality control of glycoproteins. UDP-glucose
is the glucose donor substrate for glucosylation of denatured
domains of newly synthesized glycoproteins (Hirschberg
et al., 1998). Like UDP-sugars, ATP is also transported to and
used as an energy source within the ER/Golgi (Hirschberg
et al., 1998). Nucleotides imported to the lumen of the ER
and Golgi reach concentrations up to 20-fold higher than
their cytosolic levels, and are not transported back to the
cytosol (Hirschberg et al., 1998). Therefore, they are likely to
be delivered as cargo molecules and released from cells
during glycoprotein secretion. Our data illustrating that
UDP-glucose release was inhibited by BFA (Figure 5b) further
suggest (although do not prove) that nucleotides were
released from the secretory pathway.
However, the hypothesis that nucleotide release is asso-
ciated with agonist-promoted vesicle exocytosis has been
difficult to test in 1321N1 cells, using styryl fluorophores, for
example, FM 1-43 (Kreda et al., 2007; Tatur et al., 2008).
Unlike most cells, 1321N1 cells displayed a steady, robust
increase of FM 1-43- (or its analogues FM 2-10 or FM 1-64)
associated fluorescence in the absence of stimuli, which
precluded using these protocols to assess thrombin-pro-
moted exocytosis in these cells (Kreda SM, unpublished
data). Lowering the temperature has been used to assess the
contribution of exocytosis to nucleotide release in several
cell types. However, incubating 1321N1 cells at 16 1C
markedly inhibited agonist-promoted [3H]inositol phos-
phate formation (495% inhibition, data not shown),
discouraging us from assessing the effect of temperature
changes on agonist-evoked UDP-glucose release.
Regardless of the cellular pathways and mechanism(s)
regulating UDP-glucose release from astrocytes, an under-
standing of the physiological processes regulated by the
UDP-glucose-sensing P2Y14 receptor in glial cells and astro-
cytes is now emerging (Fumagalli et al., 2003; Lee et al., 2003;
Moore et al., 2003; Skelton et al., 2003; Bianco et al., 2005;
Abbracchio and Verderio, 2006; Kobayashi et al., 2006).
P2Y14 receptor transcripts (Chambers et al., 2000), as well as
P2Y14 receptor-associated immunoreactivity (Moore et al.,
2003), are abundantly detected through several regions of
the brain. Immunohistochemistry analysis of post-mortem
human brain suggests that P2Y14 receptor localizes specifi-
cally to astrocytes. Functional evidence of P2Y14 receptor
expression in astrocytes has been suggested by studies
illustrating UDP-glucose-promoted Ca2þ mobilization in
primary cultures of rat glial cells and cortical astrocytes
(Fumagalli et al., 2003; Bianco et al., 2005). Expression of
P2Y14 receptor mRNA in the rat brain is upregulated by
immunological challenge (Moore et al., 2003; Bianco et al.,
2005), suggesting that the receptor is involved in reactive
astrogliosis.
PAR-activated astrocytes (Wang and Reiser, 2003) may be
an additional source of regulated release of UDP-glucose. The
interstitial fluid volume in the brain has been estimated to be
approximately 200 ml g1 (Friden et al., 2007). As there are
1–5 trillion cells in the adult human brain (B1.4 kg weight),
a conservative estimation of the volume of the interstitial
fluid surrounding the cells would yield 200 nl per 106 cells.
UDP-glucose released to the bulk medium following throm-
bin stimulation represented approximately 3 pmol per 106
cells (Figure 2). Therefore, on the basis of these assumptions,
UDP-glucose concentration in the undiluted extracellular
milieu of PAR-stimulated astrocytes could approach a value
of 10–20 mM, which is in the range for promoting robust
P2Y14 receptor activation (Chambers et al., 2000; Lazarowski
et al., 2003b).
In summary, our study illustrates, for the first time, the
occurrence of Ca2þ -dependent release of UDP-glucose in
receptor-stimulated 1321N1 astrocytes. Thus, UDP-glucose
release reflects a physiologically regulated mechanism of
nucleotide release, as opposed to nucleotide leakage from
damaged cells. Demonstration of the regulated release of
UDP-glucose, the most potent and selective naturally
occurring P2Y14 receptor agonist, provides compelling
evidence that, in addition to its well-established role in
metabolic reactions, this nucleotide-sugar plays important
roles in intercellular signalling.
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